Objective To analyze the efficacy and toxicities of S-1 for advanced or recurrent gastric cancer. Methods Twenty-eight patients with advanced or recurrent gastric cancer were treated with S-1. The disease con-trol rate,progression-free survival and overall survival were analyzed. Results The disease control rate was 39. 3%. The median progression-free survival was 4. 0 months(95% CI,2. 1 to 59 months);the median progres-sion-free survival of the advanced patients was 5. 9 months(95% CI,3. 1 to 8. 5 months),and the median progres-sion-free survival of the recurrent patients was 3. 1 months(95% CI,1. 9 to 4. 6 months). The median overall sur-vival was 10. 5 months(95% CI,6. 2 to 16. 1 months);the median overall survival of the advanced patients was 10. 0 months(95% CI,4. 7 to 14. 9 months),and the median overall survival of the recurrent patients was 14. 2 months(95% CI,4. 5 to 24. 1 months). The incidence rate of gradeⅢorⅣtoxicities was 10. 7%. Conclusion S-1 is safe and effective for the patients with advanced or recurrent gastric cancer.%目的：分析晚期或复发性胃癌患者应用替吉奥单药治疗后的疗效、毒副反应。方法28例患者根据体表面积给予替吉奥胶囊治疗，并评价患者的疾病控制率、无进展生存期和生存期。结果替吉奥对晚期胃癌和复发性胃癌的疾病控制率为39.3%。中位无进展生存期为4.0个月（95% CI，2.1~5.9个月），晚期胃癌患者的中位无进展生存期为5.9个月（95% CI，3.1~8.5个月），复发性胃癌的PFS中位值为3.1个月（95% CI，1.9~4.6个月）。中位生存期为10.5个月（95% CI，6.2~16.1个月），晚期胃癌患者的中位生存期为10.0个月（95% CI，4.7~14.9个月），复发性胃癌患者的中位生存期为14.2个月（95% CI，4.5~24.1个月）。Ⅲ、Ⅳ度毒副反应的发生率为10.7%。结论替吉奥治疗晚期或复发性胃癌安全有效，能延长患者生存期。
展开▼
